Stereotactic Radiosurgery System Research Articles

Risk Assessment of ZAP-X→ Radiosurgery System in a Quaternary Care Hospital Using FMEA Approach

Background and Aims: The overarching goal of this study is to conduct a robust risk assessment using the Failure Modes and Effects Analysis (FMEA) approach. By identifying potential failure modes and their potential impacts on patient care and hospital operations, this research seeks to provide actionable insights and mitigation strategies for the safe and effective implementation of the ZAP-X Radiosurgery System. The swift integration of advanced medical technologies, exemplified by the ZAP-X→ Gyroscopic Stereotactic Radiosurgery System, a computer-controlled machine that delivers radiation to an intended target in the brain, necessitates a comprehensive proactive risk assessment before the launch of the system to ensure the safety of patients, staff and operational processes. Method: Applying the FMEA methodology, we meticulously mapped all processes and sub-processes associated with the ZAP-X Radiosurgery System implementation. Our multidisciplinary team, through a discussion on ‘what can go wrong’, identified failure modes. Risks were prioritised based on severity, likelihood and detectability giving them a Risk Priority Number (RPN). The team proposed mitigation strategies, deploying controls to enhance safety and reliability.

Commissioning and clinical evaluation of a novel high-resolution quality assurance digital detector array for SRS and SBRT.

We aimed to perform the commissioning and clinical evaluation of myQA SRS detector array for patient-specific quality assurance (PSQA) of stereotactic radiosurgery (SRS)/ stereotactic body radiotherapy (SBRT) plans. To perform the commissioning of myQA SRS, its dose linearity, dose-rate dependence, angular dependence, and field-size dependence were investigated. Ten SBRT plans were selected for clinical evaluation: 1) Common clinical deviations based on the original SBRT plan (Plan0), including multileaf collimator (MLC) positioning deviation and treatment positioning deviation were introduced. 2) Compared the performance of the myQA SRS and a high-resolution EPID dosimetry system in PSQA measurement for the SBRT plans. Evaluation parameters include gamma passing rate (GPR) and distance-to-agreement (DTA) pass rate (DPR). The dose linearity, angle dependence, and field-size dependence of myQA SRS system exhibit excellent performance. The myQA SRS is highly sensitive in the detection of MLC deviations. The GPR of (3%/1mm) decreases from 90.4% of the original plan to 72.7%/62.9% with an MLC outward/inward deviation of 3mm. Additionally, when the setup error deviates by 1mm in the X, Y, and Z directions with the GPR of (3%/1mm) decreasing by an average of -20.9%, -25.7%, and -24.7%, respectively, and DPR (1mm) decreasing by an average of -33.7%, -32.9%, and -29.8%. Additionally, the myQA SRS has a slightly higher GPR than EPID for PSQA, However, the difference is not statistically significant with the GPR of (3%/1mm) of (average 90.4%% vs. 90.1%, p=0.414). Dosimetry characteristics of the myQA SRS device meets the accuracy and sensitivity requirement of PSQA for SRS/SBRT treatment. The dose rate dependence should be adequately calibrated before its application and a more stringent GPR (3%/1mm) evaluation criterion is suggested when it is used for SRS/SBRT QA.

Lexicographic Optimization-Based Planning for Single and Multiple Brain Metastasis Radiosurgery with Coplanar Arcs

This study validated a not yet commercially available fully-automated lexicographic optimization planning system (LOps) for single and multiple lesions intracranial stereotactic radiosurgery (SRS). Forty-four consecutive SRS treatment plans (21 Gy/1 fx) delivered between November 2019 and August 2022 were retrospectively selected and automatically re-planned by LOps: 25 of them has 1 lesion, 13 had 2 lesions, 4 had 3 lesions, and 2 had 4 lesions. An a-priori assigned priority list, Wish List (WL), was used to define the sequential LO: 4 patient sets (tuning set) were necessary to tune each WL, for single lesion-plans (SLp) and multiple lesion-plans (MLp). While in manual plans (MP), the arc setup is freely chosen, the WL was tuned to use 2 coplanar arcs of 140° and 360° for SLp and MLp, respectively. A 0° and 90° collimator rotation were set for counter-clockwise and clockwise arcs, respectively. The fluence optimization is followed by a Monte Carlo calculation (MCc) with 1 mm-dose grid and 0.5%-statistical uncertainty. A target coverage as high as possible was requested, with at least 80% of the prescription dose covering 99% of the PTV. The main criteria for SLp approval were a brain V12Gy <10 cm3. In MLp this criterion can be overcome to get the minimum target coverage. The remaining 36 SRS plans (21 SL and 15 MLp) were automatically re-planned (testing set). Testing plans were compared in terms of dose-volume constraints, conformality, and monitor units (MUs). Statistical significance was assessed by performing the Wilcoxon test and plan delivery accuracy was verified by pre-treatment QA. WLs-tuning took 3 days. Overall manual and automatic MCc time can be estimated at 8 hours and 3 hours, respectively. Statistically significant increases in SLp and MLp target coverage (GTV_D98%: +3.0% SL, +5.7% ML, PTV_D98%: +4.4% SL, +13.4% ML) and conformity index were registered. Automatic plans showed acceptably higher median brain V12Gy (SL: MP 7.2 cm3, SLp 7.6 cm3; ML: MP 8.7 cm3, MLp 10.3 cm3). The SLp registered a lower median MU number (-4.2%) while MLp were obtained with a higher median number of MU (+9.8%). This not statistically significant difference did not affect gamma passing rates. The novel LOps produced high-quality clinically acceptable SRS SL and ML plans with coplanar arcs according to institutional-specific planning protocols, significantly reducing the overall planning time from about one working day for one MP to about 3 hours for one automatic plan. Together with comparable OAR sparing, the target coverage was significantly increased and the plan deliverability preserved.

Commissioning and clinical evaluation of the IDENTIFYTM surface imaging system for frameless stereotactic radiosurgery.

To commission and assess the clinical performance of a new commercial surface imaging (SI) system by analyzing intra-fraction motion from the initial cohort of patients treated with frameless stereotactic radiosurgery (fSRS). The IDENTIFYTM SI system was commissioned for clinical use on an Edge (Varian Medical Systems, Palo Alto, CA) linear accelerator. All patients who received intracranial radiotherapy with HyperArcTM (Varian Medical Systems, Palo Alto, CA) were immobilized with the EncompassTM (Qfix, Avondale, PA) thermoplastic mask and monitored for intra-fraction motion with SI. IDENTIFYTM log files were correlated with trajectory log files to correlate treatment parameters with SI-reported offsets. IDENTIFYTM reported offsets were correlated with gantry and couch angles to assess system performance for obstructed and clear camera field of view. Data were stratified by race to evaluate performance differences due to skin tone. All commissioning data were found to meet recommended tolerances. IDENTIFYTM was used to monitor intra-fraction motion on 1164 fractions from 386 patients. The median magnitude of translational SI reported offsets at the end of treatment was 0.27mm. SI reported offsets were shown to increase when camera pods are blocked by the gantry with larger increases seen at non-zero couch angles. With camera obstruction, the median magnitude of the SI reported offset was 0.50 and 0.80mm for White and Black patients, respectively. IDENTIFYTM performance during fSRS is comparable to other commercially available SI systems where offsets are shown to increase at non-zero couch angles and during camera pod blockage.

Technical note: Comprehensive evaluations of gantry and couch rotation isocentricities for implementing proton stereotactic radiosurgery.

Mechanical accuracy should be verified before implementing a proton stereotactic radiosurgery (SRS) program. Linear accelerator (Linac)-based SRS systems often use electronic portal imaging devices (EPIDs) to verify beam isocentricity. Because proton therapy systems do not have EPID, beam isocentricity tests of proton SRS may still rely on films, which are not efficient. To validate that our proton SRS system meets mechanical precision requirements and to present an efficient method to evaluate the couch and gantry's rotational isocentricity for our proton SRS system. A dedicated applicator to hold brass aperture for proton SRS system was designed. The mechanical precision of the system was tested using a metal ball and film for 11 combinations of gantry and couch angles. A more efficient quality assurance (QA) procedure was developed, which used a scintillator device to replace the film. The couch rotational isocentricity tests were performed using orthogonal kV x-rays with the couch rotated isocentrically to five positions (0°, 315°, 270°, 225°, and 180°). At each couch position, the distance between the metal ball in kV images and the imaging isocenter was measured. The gantry isocentricity tests were performed using a cone-shaped scintillator and proton beams at five gantry angles (0°, 45°, 90°, 135°, and 180°), and the isocenter position and the distance of each beam path to the isocenter were obtained. Daily QA procedure was performed for 1month to test the robustness and reproducibility of the procedure. The gantry and couch rotational isocentricity exhibited sub-mm precision, with most measurements within ±0.5mm. The 1-month QA results showed that the procedure was robust and highly reproducible to within ±0.2mm. The gantry isocentricity test using the cone-shaped scintillator was accurate and sensitive to variations of ±0.2mm. The QA procedure was efficient enough to be completed within 30min. The 1-month isocentricity position variations were within 0.5mm, which demonstrating that the overall proton SRS system was stable and precise. The proton SRS Winston-Lutz QA procedure using a cone-shaped scintillator was efficient and robust. We were able to verify radiation delivery could be performed with sub-mm mechanical precision.

Preliminary dosimetric comparison between fixed and rotating source stereotactic radiosurgery systems.

The Akesis Galaxy RTi (AK) is a novel rotational 60 Co-based cranial stereotactic radiosurgery (SRS) system. While similar systems have been compared against the fixed-source Leksell Gamma Knife (GK) system using stylized phantoms, dosimetric plan quality with realistic anatomy has yet to be characterized for this or any other rotating system versus GK. This study aims to benchmark AK dosimetric performance against GK by retrospectively replanning previously-treated GK patients at our institution. Thirteen patients, previously treated on a GK Icon, were re-planned on the AK treatment planning system using the same prescription doses and isodoses as the original GK plans. The cohort includes patients treated for brain metastases, schwannomas, pituitary adenomas, trigeminal neuralgias, and arteriovenous malformations. Plans are evaluated with target coverage metrics (Dmin , Dmean , D95% , V150% ) and dose conformality indices: Radiation Therapy Oncology Group conformity index (CI), selectivity, Paddick CI (PCI), gradient index (GI). AK plans use fewer shots and larger collimation compared to GK plans, resulting in statistically significant reductions in treatment time (p=0.047) by as much as 88.4 minutes while maintaining comparable target V100% . For most metastatic cases, GK produces higher Dmin (16.0-25.9 vs. 12.5-24.3Gy, p=0.008) while AK produces higher V150% (0.03-14.92 vs. 0.02-11.59 cc, p=0.028). For non-metastatic cases, GK provides superior CI (p=0.025) and GI (p=0.044). No statistically significant differences were found in the remaining metrics. This cohort demonstrates that the AK system is able to achieve largely comparable dosimetric results to GK, typically with shorter treatment times. Further investigation with a larger cohort is underway.

Extending the EclipseTM AcurosXB output factor table for small field radiosurgery.

To investigate the necessity of extending the output factor table (OF Table) of the Varian EclipseTM Treatment Planning System for small field stereotactic radiosurgery (SRS) and stereotactic body radiosurgery (SBRT) treatments. A new AcurosXB 15.6 beam model was created in the Eclipse Beam Configuration, which is identical to the one that has been used in the clinic with a default 3×3cm to 40×40cm OF Table, except the OF Table in the new model was extended to cover the range from 1×1cm to 40×40cm. 80 small square and rectangular output factors were measured on a Varian TrueBeam utilizing a Standard Imaging Exradin W2-1×1 scintillator detector, inside a PTW BeamScan water tank with 95cm SSD at 5cm depth. Cerenkov contamination was corrected using a rectangular field method (2cm×15cm field). Nine Radiosurgery plans with primary jaw setting ranging from 0.7cm to 2.0cm were evaluated by both beam models. The monitor unit (MU) differences between the two beam models were calculated for identical 3-dimensional (3D) absolute dose distributions. Output factors, measured versus Eclipse calculated, were compared down to 0.5×0.5cm primary jaw setting. For the 6FFF beam, the difference between the two beam models was ∼ 6% for 1×1cm jaw settings and 4% at 1.5×1.5cm, with the extended OF Table requiring higher MUs for the same dose prescription and same 3-dimensional isodose distribution. For the 6MV beam, the corresponding difference is ∼7.5% for 1×1cm, 5% for 1.5×1.5cm, and 3% for 2×2cm jaw settings, with the extended OF Table requiring higher MUs. For jaw settings smaller than 1×1cm, measured dose can be considerably smaller than Eclipse predicted dose, even with the OF Table extension. This is reflected by the fact that the output factor for 0.5×0.5cm, calculated via Eclipse external beam, was more than 30% greater than that measured for both 6FFF and 6MV beams. Eclipse does a satisfactory job for primary jaw sizes down to 2cm. For jaw settings smaller than 1.5cm, the OF Table in Eclipse should be extended to improve the dose calculation accuracy.

Machine performance and stability of the first clinical self-shielded stereotactic radiosurgery system: Initial 2-year experience.

This study provides insight into the overall system performance, stability, and delivery accuracy of the first clinical self-shielded stereotactic radiosurgery (SRS) system. Quality assurance procedures specifically developed for this unit are discussed, and trends and variations over the course of 2-years for beam constancy, targeting and dose delivery are presented. Absolute dose calibration for this 2.7MV unit is performed to deliver 1 cGy/MU at dmax =7mm at a source-to-axis-distance (SAD) of 450mm for a 25mm collimator. Output measurements were made with 2-setups: a device that attaches to a fixed position on the couch (daily) and a spherical phantom that attaches to the collimating wheel (monthly). Beam energy was measured using a cylindrical acrylic phantom at depths of 100 (D10 ) and 200 (D20 )mm. Beam profiles were evaluated using Gafchromic film and compared with TPS beam data. Accuracy in beam targeting was quantified with the Winston-Lutz (WL) and end-to-end (E2E) tests. Delivery quality assurance (DQA) was performed prior to clinical treatments using Gafchromic EBT3/XD film. Net cumulative output adjustments of 15% (pre-clinical), 9% (1st year) and 3% (2nd year) were made. The mean output was 0.997±0.010 cGy/MU (range: 0.960-1.046cGy/MU) and 0.993±0.029 cGy/MU (range: 0.884-1.065cGy/MU) for measurements with the daily and monthly setups, respectively. The mean relative beam energy (D10 /D20 ) was 0.998±0.004 (range: 0.991-1.006). The mean total targeting error was 0.46±0.17mm (range: 0.06-0.98mm) for the WL and 0.52±0.28mm (range: 0.11-1.27mm) for the E2E tests. The average gamma pass rates for DQA measurements were 99.0% and 90.5% for 2%/2mm and 2%/1mm gamma criteria, respectively. This SRS unit meets tolerance limits recommended by TG-135, MPPG 9a., and TG-142 with a treatment delivery accuracy similar to what is achieved by other SRS systems.

Comparison of survival outcomes after CyberKnife® radiotherapy in Taiwan using preapproved insurance-based reimbursement versus out-of-pocket expenditure.

Background:With technological advances, radiotherapy has progressed from simple irradiation to robotic arm-based stereotactic radiosurgery systems (SRS, in this case, CyberKnife®). This equipment is high-priced and might be cost-effective or not. The National Health Insurance (NHI) in Taiwan has a premedical claims review process for approving CyberKnife® treatment; however, patients might have to pay for the procedure themselves if the NHI rejects the practice. Under the high treatment cost and such an insurance system, a sketch of patients treated by these high-cost machines and whether the prereview of insurance for reimbursement is reasonable without hindering the patient’s right to undergo treatment should be investigated. In this study, the patients of CyberKnife® radiotherapy in our institute were investigated as an example for this purpose.Methods:Patients who underwent CyberKnife® radiotherapy in our department were investigated retrospectively. Their demographic characteristics, disease patterns, and treatment sites were analyzed. Survivals were compared according to clinical features, and treatment expenses were reimbursed after prereview or out-of-pocket.Results:From October 19, 2014, to January 30, 2018, there were 331 patients included in this study, 205 (55.3%) of whom underwent CyberKnife® radiotherapy at their own expense, while 166 (44.7%) had their expenses approved for reimbursement after prereview by NHI. Most patients were treated for metastatic tumors (37.5%), and the brain was the most frequent treatment site (46.1%). The 1-year overall survival was 67.1%, and the 2-year overall survival was 56.3% after CyberKinfe® radiotherapy. The best survival rate (96.8% at 1 year) was for patients with brain tumors. In patient’s characteristics, A better Eastern Cooperative Oncology Group (ECOG) performance status, treatment for primary tumors, and outpatient treatment were independent factors for superior survival after CyberKnife® radiotherapy. The survivals for patients whose treatment expenses were approved for reimbursement after prereview by NHI were also better than out-of-pocket.Conclusions:Besides the patients’ characteristics, the treatment expense could be approved or rejected for reimbursement by the NHI prereview was an independent factor for survival in CyberKnife® radiotherapy. Prereview to reimburse expensive treatment is not an unreasonable requirement.

Comparative study of SRS end-to-end QA processes of a diode array device and an anthropomorphic phantom loaded with GafChromic XD film.

PurposeEnd‐to‐end testing (E2E) is a necessary process for assessing the readiness of the stereotactic radiosurgery (SRS) program and annual QA of an SRS system according to the AAPM MPPG 9a. This study investigates the differences between using a new SRS MapCHECK (SRSMC) system and an anthropomorphic phantom film‐based system in a large network with different SRS delivery techniques.Methods and materialsThree SRS capable Linacs (Varian Medical Systems, Palo Alto, CA) at three different regional sites were chosen to represent a hospital network, a Trilogy with an M120 multi‐leaf collimator (MLC), a TrueBeam with an M120 MLC, and a TrueBeam Stx with an HD120 MLC. An anthropomorphic STEEV phantom (CIRS, Norfolk, VA) and a phantom/diode array: StereoPHAN/SRSMC (Sun Nuclear, Melbourne, FL) were CT scanned at each site. The new STV‐PHANTOM EBT‐XD films (Ashland, Bridgewater, NJ) were used. Six plans with various complexities were measured with both films and SRSMC in the StereoPHAN to establish their dosimetric correlations. Three SRS cranial plans with a total of sixteen fields using dynamic conformal arc and volumetric‐modulated arc therapy, with 1–4 targets, were planned with Eclipse v15.5 treatment planning system (TPS) using a custom SRS beam model for each machine. The dosimetric and localization accuracy were compared. The time of analysis for the two systems by three teams of physicists was also compared to assess the throughput efficiency.ResultsThe correlations between films and SRSMC were found to be 0.84 (p = 0.03) and 0.16 (p = 0.76) for γ (3%, 1 mm) and γ (3%, 2 mm), respectively. With film, the local dose differences (ΔD) relative to the average dose within the 50% isodose line from the three sites were found to be −3.2%–3.7%. The maximum localization errors (Elocal) were found to be within 0.5 ± 0.2 mm. With SRSMC, the ΔD was found to be within 5% of the TPS calculation. Elocal were found to be within 0.7 to 1.1 ± 0.4 mm for TrueBeam and Trilogy, respectively. Comparing with film, an additional uncertainty of 0.7 mm was found with SRSMC. The delivery and analysis times were found to be 6 and 2 h for film and SRSMC, respectively.ConclusionsThe SRS MapCHECK agrees dosimetrically with the films within measurement uncertainties. However, film dosimetry shows superior sub‐millimeter localization resolving power for the MPPG 9a implementation.

Comparison of intrafractional motion with two frameless immobilization systems in surface-guided intracranial stereotactic radiosurgery.

Purpose/objectivesThe aim of this study is to compare intrafractional motion using two commercial non‐invasive immobilization systems for linac‐based intracranial stereotactic radiosurgery (SRS) under guidance with a surface‐guided radiotherapy (SGRT) system.Materials/methodsTwenty‐one patients who received intracranial SRS were retrospectively selected. Ten patients were immobilized with a vacuum fixation biteplate system, while 11 patients were immobilized with an open‐face mask system. A setup margin of 1 mm was used in treatment planning. Real‐time surface motion data in 37 treatment fractions using the vacuum fixation system and 44 fractions using the open‐face mask were recorded by an SGRT system. Variances of intrafractional motion along three translational directions and three rotational directions were compared between the two immobilization techniques with Levene's tests. Intrafractional motion variation over time during treatments was also evaluated.ResultsUsing the vacuum fixation system, the average and standard deviations of the shifts were 0.01 ± 0.18 mm, ‐0.06 ± 0.30 mm, and 0.02 ± 0.26 mm in the anterior–posterior (AP), superior–inferior (SI), and left–right (LR) directions, and ‐0.02 ± 0.19°, ‐0.01 ± 0.13°, and 0.01 ± 0.13° for rotations in yaw, roll, and pitch, respectively; using the open‐face mask system, the average and standard deviations of the shifts were ‐0.06 ± 0.20 mm, ‐0.02 ± 0.35 mm, and 0.01 ± 0.40 mm in the AP, SI, and LR directions, and were 0.05 ± 0.23°, 0.02 ± 0.21°, and 0.00 ± 0.16° for rotations in yaw, roll, and pitch, respectively. There was a significant increase in intrafractional motion variance over time during treatments.ConclusionPatients with the vacuum fixation system had significantly smaller intrafractional motion variation compared to those with the open‐face mask system. Using intrafractional motion techniques such as surface imaging system is recommended to minimize dose deviation due to intrafractional motion. The increase in intrafractional motion over time indicates clinical benefits with shorter treatment time.

Small-field beam data acquisition, detector dependency, and film-based validation for a novel self-shielded stereotactic radiosurgery system.

This study reports a single-institution experience with beam data acquisition and film-based validation for a novel self-shielded sterotactic radiosurgery unit and investigates detector dependency on field output factors (OFs), off-axis ratios (OARs), and percent depth dose (PDD) measurements within the context of small-field dosimetry. The delivery platform for this unit consists of a 2.7-MV S-band linear accelerator mounted on coupled gimbals that rotate around a common isocenter (source-to-axis distance [SAD]=450mm), allowing for more than 260 noncoplanar beam angles. Beam collimation is achieved via a tungsten collimator wheel with eight circular apertures ranging from 4mm to 25mm in diameter. Three diodes (PTW 60012 Diode E, PTW 60018 SRS Diode, and Sun Nuclear EDGE) and a synthetic diamond detector (PTW 60019micro Diamond [µD] detector) were used for OAR, PDD, and OF measurements. OFs were also acquired with a PTW 31022 PinPoint ionization chamber. Beam scanning was performed using a 3D water tank at depths of 7, 50, 100, 200, and 250mm with a source-to-surface distance of 450mm. OFs were measured at the depth of maximum dose (dmax =7mm) with the SAD at 450mm. Gafchromic EBT3 film was used to validate OF and profile measurements and as a reference detector for estimating correction factors for active detector OFs. Deviations in field size, penumbra, and PDDs across the different detectors were quantified. Relative OFs (ROFs) for the diodes were within 1.4% for all collimators except for 5 and 7.5mm, for which SRS Diode measurements were higher by 1.6% and 2.6% versus Diode E. The µD ROFs were within 1.4% of the diode measurements. PinPoint ROFs were lower by >10% for the 4-mm and 5-mm collimators versus the Diode E and µD. Corrections to OFs using EBT3 film as a reference were within 1.2% for all diodes and the µD detector for collimators 10mm and greater and within 2.0%, 2.8%, and 1.1% for the 7.5-, 5-, and 4-mm collimators, respectively. The maximum difference in full width at half maximum (FWHM) between the Diode E and the other active detectors was for the 25-mm collimator and was 0.09mm (µD), 0.16mm (SRS Diode), and 0.65mm (EDGE). Differences seen in PDDs beyond the depth of dmax were <1% across the three diodes and the µD. FWHM and penumbra measurements made using EBT3 film were within 1.34% and 3.26%, respectively, of the processed profile data entered into the treatment planning system. Minimal differences were seen in OAR and PDD measurements acquired with the diodes and the µD. ROFs measured with the three diodes were within 2.6% and within 1.4% versus the µD. Gafchromic Film measurements provided independent verification of the OAR and OF measurements. Estimated corrections to OFs using film as a reference were <1.6% for the Diode E, EDGE, and µD detector.

Frameless immobilization system with roll correction for stereotactic radiosurgery of intracranial brain metastases.

The objectives of this study were to develop a frameless immobilization system that allows roll rotation corrections and to investigate the performance of this system for stereotactic radiosurgery (SRS) treatment. We designed the support frame of a frameless immobilization system based on the commercial Brainlab immobilization system. The support frame consisted of a fixed component and a rotating component. With rack and pinion gears and guide holes installed in the system, the rotating component was configured to be rotated along the longitudinal axis of the patient with respect to the fixed component. To evaluate the performance of the system, the six degree-of-freedom (6D) positioning corrections (translational and rotational corrections) were assessed by image verification between planning computed tomography (CT) and cone-beam computed tomography (CBCT) images. The commercial immobilization system was evaluated in the same manner for comparison. The mean translational shifts for the commercial system were 0.68 ± 0.19mm, 0.73 ± 0.24mm and 0.78 ± 0.19mm, while those for the developed system were 0.44 ± 0.31mm, 0.43 ± 0.25mm and 0.60 ± 0.14mm in the lateral, longitudinal and vertical directions, respectively. The mean rotational shifts for the commercial system were 0.37° ± 0.12°, 0.32° ± 0.16° and 0.38° ± 0.14°, while those for the developed system were 0.04° ± 0.04°, 0.11° ± 0.06° and 0.15° ± 0.12° along the lateral, vertical and longitudinal axes of the patient, respectively. For institutions that do not have 6D robotic couches installed, the use of the developed immobilization system can provide 6D corrections, resulting in shorter treatment times and higher patient positioning accuracy.

PO-1715 Accuracy of a dedicated single isocenter stereotactic radiosurgery system for multiple brain lesions

PO-1715 Accuracy of a dedicated single isocenter stereotactic radiosurgery system for multiple brain lesions

Design and characterization of a prototype tertiary device for proton beam stereotactic radiosurgery

Though potentially beneficial, proton beam stereotactic radiosurgery has not been adopted widely secondary to the technical challenge of safely delivering multiple focused beams of proton radiation. In this study, we describe the design and characterization of a proton beam stereotactic radiosurgery system that can be adopted by existing passive scattering systems. This system utilizes a helmet-like device in which patient-specific brass apertures required for final beam collimation are positioned on a scaffold that is separate from the treatment gantry. The proton snout is then fitted with a generic aperture to focus the primary proton beam onto the patient specific apertures that are in the helmet-like device. The patient-specific apertures can all be placed at the start of the treatment, thus treatment with multiple beams can be accomplished without the delay of switching the apertures. In this report we describe a prototype design of this collimation system and dosimetric testing to verify efficacy. Subsequently, we describe a custom 3D printing of a prototype device and report on overall localization accuracy using Winston-Lutz tests. Our results show that it is possible to develop an add-on device for proton beam radiosurgery that is safe and efficient and capable of wide adoption on existing proton delivery systems.

Treatment planning system and beam data validation for the ZAP-X: A novel self-shielded stereotactic radiosurgery system.

To evaluate the treatment planning system (TPS) performance of the ZAP-X stereotactic radiosurgery (SRS) system through nondosimetric, dosimetric, and end-to-end (E2E) tests. A comprehensive set of TPS commissioning and validation tests was developed using published guidelines. Nondosimetric validation tests included information transfer, computed tomography-magnetic resonance (CT-MR) image registration, structure/contouring, geometry, dose tools, and CT density. Dosimetric validation included comparisons between TPS and water tank/Solid Water measurements for various geometries and beam arrangements and end-to-end (E2E) tests. Patient-specific quality assurance was performed with an ion chamber in the Lucy phantom and with Gafchromic EBT3 film in the CyberKnife head phantom. RadCalc was used for independent verification of monitor units. Additional E2E tests were performed using the RPC Gamma Knife thermoluminescent dosimeter (TLD) phantom, MD Anderson SRS head phantom, and PseudoPatient gel phantom for independent absolute dose verification. CT-MR image registrations with known translational and rotational offsets were within tolerance (<0.5×maximum voxel dimension). Slice thickness and distance accuracy were within 0.1mm, and volume accuracy was within 0 to 0.11cm3 . Treatment planning system volume measurement uncertainty was within 0.1 to 0.4cm3 . Ion chamber point-dose measurements for a single beam in a water phantom agreed to TPS-calculated values within ±4% for collimator diameters 10 to 25mm, and ±6% for 7.5mm, for all measured depths (7, 50, 100, 150, and 200mm). In homogeneous Solid Water, point-dose measurements agreed to within ±4% for cones sizes 7.5 to 25mm. With 1-cm high/low density inserts, measurements were within ±4.2% for cone sizes 10 to 25mm. Film-based E2E using 4/5-mm cones resulted in a gamma passing rate (%GP) of 99.8% (2%/1.5mm). Point-dose measurements in a Lucy phantom with an ion chamber using 36 beams distributed along three noncoplanar arcs agreed to within ±4% for cone sizes 10 to 25mm. The RPC Gamma Knife TLD phantom yielded passing results with a measured-to-expected TLD dose ratio of 1.02. The MD Anderson SRS head phantom yielded passing results, with 4% TLD agreement and %GP of 95%/93% (5%/3mm) for coronal/sagittal film planes. The RTsafe gel phantom gave %GP of >95% (5%/2mm) for all four targets. For our first 58 patients, film-based patient-specific quality assurance has resulted in an average %GP of 98.7% (range, 94-100%) at 2%/2mm. Core ZAP-X features were found to be functional. On the basis of our results, point-dose and planar measurements were in agreement with TPS calculations using multiple phantoms and setup geometries, validating the ZAP-X TPS beam model for clinical use.

Commissioning of optical surface imaging systems for cranial frameless stereotactic radiosurgery.

PurposeThis study aimed to evaluate and compare different system calibration methods from a large cohort of systems to establish a commissioning procedure for surface‐guided frameless cranial stereotactic radiosurgery (SRS) with intrafractional motion monitoring and gating. Using optical surface imaging (OSI) to guide non‐coplanar SRS treatments, the determination of OSI couch‐angle dependency, baseline drift, and gated‐delivered‐dose equivalency are essential.MethodsEleven trained physicists evaluated 17 OSI systems at nine clinical centers within our institution. Three calibration methods were examined, including 1‐level (2D), 2‐level plate (3D) calibration for both surface image reconstruction and isocenter determination, and cube phantom calibration to assess OSI‐megavoltage (MV) isocenter concordance. After each calibration, a couch‐angle dependency error was measured as the maximum registration error within the couch rotation range. A head phantom was immobilized on the treatment couch and the isocenter was set in the middle of the brain, marked with the room lasers. An on‐site reference image was acquired at couch zero, the facial region of interest (ROI) was defined, and static verification images were captured every 10° for 0°–90° and 360°–270°. The baseline drift was assessed with real‐time monitoring of the motionless phantom over 20 min. The gated‐delivered‐dose equivalency was assessed using the electron portal imaging device and gamma test (1%/1mm) in reference to non‐gated delivery.ResultsThe maximum couch‐angle dependency error occurs in longitudinal and lateral directions and is reduced significantly (P < 0.05) from 1‐level (1.3 ± 0.4 mm) to 2‐level (0.8 ± 0.3 mm) calibration. The MV cube calibration does not further reduce the couch‐angle dependency error (0.8 ± 0.2 mm) on average. The baseline drift error plateaus at 0.3 ± 0.1 mm after 10 min. The gated‐delivered‐dose equivalency has a >98% gamma‐test passing rate.ConclusionA commissioning method is recommended using the 3D plate calibration, which is verified by radiation isocenter and validated with couch‐angle dependency, baseline drift, and gated‐delivered‐dose equivalency tests. This method characterizes OSI uncertainties, ensuring motion‐monitoring accuracy for SRS treatments.

Characterization of the ZAP-X® Peripheral Dose Fall-Off.

Various small-field radiation dose detectors were systematically compared and their impact on measured beam performance of the ZAP-X® dedicated stereotactic radiosurgery system (ZAP Surgical Systems, Inc., San Carlos, CA, USA) was determined. Three Physikalische Technische Werkstaetten (PTW) diodes, i.e., the microSilicon, the microDiamond, and the Stereotactic Radiosurgery (SRS) diode detectors of (PTW-Freiburg, Freiburg, Germany), as well as Gafchromic™ External Beam Therapy 3 (EBT) film (Ashland, Inc., Wilmington, DE, USA), were used and compared to arrive at a recommended standard for this critical component of small-field beam measurements. Beam profiles, including the dose fall-off region near the edge of the beam, were measured with the PTW diodes and EBT3 film and subsequently contrasted. The impact of detector physical and dosimetric characteristics on the results of the measurements was investigated and compared with film measurements. The beam penumbra was used to quantify the dose fall-off. The measurement acquired with the diodes and film showed the most significant differences in the fall-off region near the field edge. The film-based measurements clearly showed the steepest dose gradient verified by the penumbra value of 1.21 mm, followed by the SRS diode with 1.60 mm, the microSilicon diode with 1.67 mm, and the microDiamond diode with 1.83 mm. A clear correlation of each detector’s sensitive area with the penumbra was found, with the microDiamond detector at 2.2 mm diameter sensitive area having the largest penumbra, followed by the microSilicon and SRS diodes. Beam measurements for the purposes of system characterization or treatment planning system beam data acquisition depend, to a large extent, on detector characteristics. This is especially true for small-field dosimetry performed during stereotactic radiosurgery beam measurements. Careful consideration should be practiced which allows for the measurements to represent true beam characteristics and minimize the impact of the detector on the measurements. We conclude that film should be considered the reference method for such measurements with the ZAP-X due to its smallest physical measurement resolution of 23.1 µm. Potential drawbacks to this methodology are the need to calibrate the film relative to the dose and possible problems with saturation and non-linear film response for very high and very low optical densities.

Magnetic Resonance Imaging-Based Robotic Radiosurgery of Arteriovenous Malformations.

ObjectiveCyberKnife offers CT- and MRI-based treatment planning without the need for stereotactically acquired DSA. The literature on CyberKnife treatment of cerebral AVMs is sparse. Here, a large series focusing on cerebral AVMs treated by the frameless CyberKnife stereotactic radiosurgery (SRS) system was analyzed.MethodsIn this retrospective study, patients with cerebral AVMs treated by CyberKnife SRS between 2005 and 2019 were included. Planning was MRI- and CT-based. Conventional DSA was not coregistered to the MRI and CT scans used for treatment planning and was only used as an adjunct. Obliteration dynamics and clinical outcome were analyzed.Results215 patients were included. 53.0% received SRS as first treatment; the rest underwent previous surgery, embolization, SRS, or a combination. Most AVMs were classified as Spetzler-Martin grade I to III (54.9%). Hemorrhage before treatment occurred in 46.0%. Patients suffered from headache (28.8%), and seizures (14.0%) in the majority of cases. The median SRS dose was 18 Gy and the median target volume was 2.4 cm³. New neurological deficits occurred in 5.1% after SRS, with all but one patient recovering. The yearly post-SRS hemorrhage incidence was 1.3%. In 152 patients who were followed-up for at least three years, 47.4% showed complete AVM obliteration within this period. Cox regression analysis revealed Spetzler-Martin grade (P = 0.006) to be the only independent predictor of complete obliteration.ConclusionsAlthough data on radiotherapy of AVMs is available, this is one of the largest series, focusing exclusively on CyberKnife treatment. Safety and efficacy compared favorably to frame-based systems. Non-invasive treatment planning, with a frameless SRS robotic system might provide higher patient comfort, a less invasive treatment option, and lower radiation exposure.

Commissioning of the TrueBeam STx 6 MV FFF Beam in the RayStation Treatment Planning System for SRS and SBRT Treatments

Purpose: The purpose of this study is to provide technical information on commissioning the TrueBeam STx 6 MV flattening-filter free (FFF) beam in the RayStation treatment planning system (TPS) for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments. Methods: For beam modeling, percent depth dose curves, profiles and output factors for jaw-collimated fields and stereotactic cones as well as X-jaws transmission were measured. For multi-leaf collimator (MLC) modeling, MLC model parameters such as offset, gain, curvature, leaf tip width, tongue and groove and transmission were determined and output factors for MLC-collimated fields were measured. Absolute dose calibration was also performed. For beam model and MLC model validation, the American Association of Physicists in Medicine Task Group-119 plans, clinical SRS and SBRT plans and end-to-end testing were performed. Results: Beam characteristics of the 6 MV FFF beam agreed well with those in the literature. Validation results showed that our beam model and MLC model were acceptable for SRS and SBRT treatments. Conclusions: The technical information and dosimetric data provided in this study will be a useful reference for other clinics/institutions which will commission the same machine energy in the RayStation TPS.